

Seizure Log

Date ____ / ____ / ____

Seizure Log Cards
Seizure Log

Date ____ / ____ / ____

Date ____ / ____ / ____
Time seizure started: ____ Time seizure ended: ____
Time of DIASTAT® AcuDial™ administration: ____
Time 911 called: ____
Behavior on regaining consciousness:

Repeating seizure information:

© 2007. D867-3037 Valeant Pharmaceuticals North America

Seizure Log

Date ____ / ____ / ____

Date ____ / ____ / ____
Time seizure started: ____ Time seizure ended: ____
Time of DIASTAT® AcuDial™ administration: ____
Time 911 called: ____
Behavior on regaining consciousness:

Repeating seizure information:

© 2007. D867-3037 Valeant Pharmaceuticals North America

Seizure Log

Date ____ / ____ / ____

Date ____ / ____ / ____
Time seizure started: ____ Time seizure ended: ____
Time of DIASTAT® AcuDial™ administration: ____
Time 911 called: ____
Behavior on regaining consciousness:

Repeating seizure information:

© 2007. D867-3037 Valeant Pharmaceuticals North America

Date ____ / ____ / ____
Time seizure started: ____ Time seizure ended: ____
Time of DIASTAT® AcuDial™ administration: ____
Time 911 called: ____
Behavior on regaining consciousness:

Repeating seizure information:

© 2007. D867-3037 Valeant Pharmaceuticals North America

CONFIDENTIALITY STATEMENT

By creating and distributing this Seizure Preparedness Plan, it is the expressed intention of Valeant Pharmaceuticals North America to provide a value-added service to healthcare providers, caregivers, and patients. Valeant Pharmaceuticals North America intends to fully comply with HIPPA guidelines for patient confidentiality to ensure that personal information is not disclosed to anyone outside of those that the parent/caregiver, healthcare professional, or student-patient deem acceptable. Valeant Pharmaceuticals North America is not responsible for this Plan or its contents after the Plan has been released to healthcare professionals. Careful consideration should be given before any medical information is released to others.

IMPORTANT SAFTEY INFORMATION

DIASTAT® AcuDial™ (diazepam rectal gel) is a gel formulation of diazepam intended for rectal administration in the management of selected refractory patients with epilepsy, on stable regimens of AEDs, who require intermittent use of diazepam to control bouts of increased seizure activity for patients 2 years and older.

In clinical trials with DIASTAT®, the most frequent adverse event was somnolence (23%). Less frequent adverse events reported were dizziness, headache, pain, vasodilation, diarrhea, ataxia, euphoria, incoordination, asthma, rash, abdominal pain, nervousness and rhinitis (1%-5%). Please see full DIASTAT AcuDial Prescribing Information.

© 2007 Valeant Pharmaceuticals North America (INSERT PRC NUMBER: waiting on Client to provide)